# Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

> **NCT04724031** · — · UNKNOWN · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 150 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** PARP inhibitor

## Key facts

- **NCT ID:** NCT04724031
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04724031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04724031, "Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04724031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*